Inflammatory Biomarkers' Function in Cardiovascular Event Prediction
Keywords:
hazard, events, cardiovascularAbstract
The study's methodology involved enrolling 1,090 patients who had coronary angiography. Twenty-four indicators of inflammation were gathered before angiography. Distinct patterns of inflammatory biomarkers were identified by cluster analyses using unsupervised machine learning. The link between inflammatory biomarker clusters and individual biomarker associations with major adverse cardiovascular events (MACE; non-fatal myocardial infarction or stroke, and CV mortality) over a median follow-up of 3.67 years was evaluated using Cox proportional hazard regression.
References
Libby P. Atherosclerosis and inflammation. 2012;32:2045–51; Arterioscler Thromb Vasc Biol. 2.
Tedgui A, Mallat Z, Taleb S, and Ait-Oufella H. Recent developments on the part cytokines play in
atherosclerosis. 2011;31:969–79; Arterioscler Thromb Vasc Biol. October 2022, American Heart
Journal
Kalkman DN, Guedeney P, Claessen BE, et al. residual inflammatory risk in individuals
undergoing percutaneous coronary intervention who have low LDL cholesterol. 73:2401–9, J Am
Coll Cardiol, 2019.
Hansson GK, Libby P. The week's JACC review subject ranges from systemic inflammation to
localized lipid storage. 74:1594–607 in J Am Coll Cardiol, 2019.
Godoy LC, Bhatt DL, Lawler PR, et al. Clinical translation's next stages in addressing
cardiovascular inflammation. Eur Heart J 42:113–31, 2021.
Lyass A, Liu Y, Gaggin HK, et al. Myocardial infarction incident type 2 in a group of patients
receiving peripheral arterial or coronary angiography. Circulation 135:116–27, 2017.
Consoli A, Bain SC, Marso SP, et al. Cardiovascular outcomes and semaglutide in individuals with
type 2 diabetes. In 2016, N Engl J Med 375:1834–44.
Cavender MA, Abadie BQ, and Cannon CP. new oral anticoagulants after coronary artery bypass
surgery. Circ 2020; 13. Cardiovasc Interv 9. Stock JK. Future learning from studies on residual
inflammatory risk. In 2020, Atherosclerosis 311:103–4.
Libby P. The idea that inflammation causes atherosclerosis is no longer valid. 2021 Clin Chem
:131–42.
Everett BM, Thuren T, Ridker PM, et al. Canakinumab-based anti-inflammatory treatment for
atherosclerotic disease. N Engl J Med 377:1119–31, 2017.
IL-6 inhibition with ziltivekimab in patients at high atherosclerosis risk (RESCUE): a doubleblind, randomized, placebo-controlled, phase 2 study Ridker PM, Devalaraja M, Baeres FMM, et al.
Lancet 397:2060-9.
Deftereos SG, Shah B, Beerkens FJ, et al. Comprehensive overview of colchicine's role in
cardiovascular disease. Circulation 145:61–78, 2022.
Barraclough J, Robertson S, Martinez GJ, et al. Acute coronary syndrome patients' local cardiac
production of inflammatory cytokines is abruptly suppressed by colchicine. 15. Ridker PM, Everett
BM, Pradhan A, et al. J Am Heart Assoc 2015;4. Methotrexate at low doses to prevent atherosclerotic
events. 2019; N Engl J Med;380:752–62.
Ridker PM, Everett BM, MacFadyen JG, et al. A secondary analysis from the CANTOS
randomised controlled trial examined the relationship between the decrease in C-reactive protein
and the decrease in cardiovascular events after canakinumab medication. 2018;391:319–28;Lancet.
Qiao JH, Mishra NK, Tripathi J, et al. Studies on osteopetrotic mice reveal the role of macrophage
colony-stimulating factor in atherosclerosis. In 1997, Am J Pathol, 150:1687–99.
Zolindaki MG, Pentzeridis PC, Rallidis LS, et al. In severe unstable angina, elevated levels of
macrophage colony stimulating factor after the acute phase are highly indicative of long-term
results. Heart, 2004; 90:25–9.
Vasudevan SS, Kereiakes DJ, Seshiah PN, et al. The function of cell contact and macrophage
colony-stimulating factor in the smooth muscle cell death caused by activated monocytes.
Circulation 105:174–80, 2002.
Philippova M, Oskolkova O, Bochkov VN, et al. Through autocrine pathways, oxidized
phospholipids promote angiogenesis, suggesting a new function for lipid oxidation in the
development of atherosclerotic lesions. 2006;99:900–8; Circ Res.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
User Rights
Under the Creative Commons Attribution-NonCommercial 4.0 International (CC-BY-NC), the author (s) and users are free to share (copy, distribute and transmit the contribution).
Rights of Authors
Authors retain the following rights:
1. Copyright and other proprietary rights relating to the article, such as patent rights,
2. the right to use the substance of the article in future works, including lectures and books,
3. the right to reproduce the article for own purposes, provided the copies are not offered for sale,
4. the right to self-archive the article.